Introduction: Hepatitis C virus (HCV) infection is a persistent viral infection of the liver and 
considered as a considerable health dilemma globally especially in Egypt. Treatment for chronic 
hepatitis C virus infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral 
(DAA) agents. Cardiovascular diseases (CVDs), which accounted for one-third of global deaths in 
2015, are recognized as a major barrier to sustainable human development. Aim of the work: The 
aim of this study is to evaluate the effect of new antiviral treatments regarding heart failure in patients 
with chronic viral hepatitis “c". Patients and Methods: This cohort study was carried out on 100
patients with chronic heart failure and candidate for DAA therapy. Cases were taken and divided into: 
Results: The DAAs used in combination regimen with ribavirin do not significantly affect the 
cardiovascular system.